China’s Eddingpharm Deal A Fresh Start For Ablynx’s Ozoralizumab
This article was originally published in PharmAsia News
Executive Summary
Ablynx has signed a deal with Chinese company Eddingpharm for certain Asian rights to its rheumatoid arthritis drug ozoralizumab, marking a fresh start for the anti-TNF nanobody after Pfizer backed out of a global deal in 2011.